PRESEPT Study: Evaluation of SEPT9 Biomarker Performance for Colorectal Cancer Screening

CompletedOBSERVATIONAL
Enrollment

7,929

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

April 30, 2010

Conditions
Colorectal Cancer
Interventions
OTHER

All eligible subjects will provide blood for SEPT9 biomarker testing

A single blood sample per participant selected according to analysis plan is tested for evidence of methylation of a specific DNA sequence, SEPT9.

Trial Locations (23)

17604

Regional Gastroenterology Associates of Lancaster, Ltd., Lancaster

20246

University of Hamburg-Eppendorf, Hamburg

22911

Charlottesville Medical Research, Charlottesville

27103

Digestive Health Specialists, Winston-Salem

28562

Southern Gastroenterology Associates, New Bern

28801

Asheville Gastroenterology Associates PA, Asheville

29425

Medical University of South Carolina Digestive Disease Center, Charleston

30134

Atlanta Gastroenterology Associates, Atlanta

33173

GI Care Center, Miami

33486

Digestive Care, Boca Raton

38138

Gastroenterology Center of the MidSouth, Germantown

39202

Jackson Gastrointestinal Associates, Jackson

40202

University of Louisville, Louisville

50325

Heartland Medical Research, Inc., Clive

55455

Minnesota Gastroenterology, Minneapolis

61107

Rockford Gastroenterology Associates, Ltd., Rockford

97205

The Portland Clinic, Portland

97210

Northwest Gastroenterology Clinic, Portland

97220

The Oregon Clinic, Portland

98008

Northwest Gastroenterology Associates, Bellevue

98405

Tacoma Digestive Disease Research Center, Tacoma

Unknown

Berlin Private-Practice Gastroenterology Working Group, Berlin

Technical University of Munich, Munich

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Epigenomics, Inc

INDUSTRY

NCT00855348 - PRESEPT Study: Evaluation of SEPT9 Biomarker Performance for Colorectal Cancer Screening | Biotech Hunter | Biotech Hunter